IMGN853 for Endometrial Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, there is a requirement for a 'washout period' (time without taking certain medications) from prior systemic anti-neoplastic therapy, which is either five half-lives or four weeks, whichever is shorter.
What data supports the effectiveness of the drug Mirvetuximab Soravtansine (IMGN853) for endometrial cancer?
Research shows that Mirvetuximab Soravtansine is effective in treating aggressive endometrial cancers that overexpress the folate receptor alpha (FRα). In studies, it led to complete tumor resolution in certain endometrial cancer models and increased survival in uterine cancer models with high FRα expression.12345
What safety data exists for Mirvetuximab Soravtansine (IMGN853) in humans?
What makes the drug IMGN853 unique for treating endometrial cancer?
IMGN853 (Mirvetuximab Soravtansine) is unique because it specifically targets the folate receptor alpha (FRα), which is overexpressed in certain aggressive endometrial cancers. This targeted approach allows the drug to deliver a potent cancer-killing agent directly to the cancer cells, potentially improving outcomes for patients with FRα-positive tumors.14589
Research Team
Alessandro Santin
Principal Investigator
Yale University
Eligibility Criteria
This trial is for women with certain types of advanced endometrial cancer that have a protein called FRα. They must have tried ≤3 treatments, not be pregnant, agree to contraception, and can't have had certain heart issues, brain conditions or other serious health problems.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive IMGN853 at a dose of 6 mg/kg administered intravenously once every 3 weeks until unacceptable toxicity or disease progression
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Mirvetuximab Soravtansine (IMGN853)
Mirvetuximab Soravtansine (IMGN853) is already approved in United States, European Union for the following indications:
- Platinum-resistant epithelial ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Epithelial ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alessandro Santin
Lead Sponsor
ImmunoGen, Inc.
Industry Sponsor